drugset / Trial / NCT07246590
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
Phase 3
Recruiting
300 enrolled
Verrica Pharmaceuticals Inc.
Allucent (US) LLC · collabCanfield Scientific Inc. · collabMedidata Solutions · collabMyonex · collabTorii Pharmaceutical Co. Ltd. · collabVeeva Systems · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy and safety of YCANTH (VP-102) treatment in subjects with common warts.
Timeline
- Start
- 2025-12-17
- Primary completion
- 2027-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cantharidin | Small molecule | 0.7 % | Topical |